Ugrás a tartalomra
Merck
Összes fotó(3)

Fontos dokumentumok

View All Documentation

699800P

Avanti

MPLA (PHAD™)

Avanti Research™ - A Croda Brand

Szinonimák:

PHAD™ phosphorylated hexaacyl disaccharide; Glycopyranoside Lipid A; GLA

Bejelentkezésa Szervezeti és Szerződéses árazás megtekintéséhez
Összes fotó(3)

About This Item

Tapasztalati képlet (Hill-képlet):
C96H184N3O22P
CAS-szám:
1246298-63-4
Molekulatömeg:
1763.47
UNSPSC kód:
12352211
NACRES:
NA.25

leírás

Monophosphoryl Lipid A (Synthetic) (PHAD™)

Teszt

>99% (HPLC)

form

powder

kiszerelés

pkg of 1 × 1 mg (699800P-1mg)
pkg of 1 × 5 mg (699800P-5mg)

gyártó/kereskedő neve

Avanti Research™ - A Croda Brand

alkalmazás(ok)

vaccine development

kiszállítva

dry ice

tárolási hőmérséklet

−20°C

Általános leírás

Monophosphoryl lipid A (MPLA) is either extracted from bacterial lipid A or by chemical synthesis.
Vaccination is well-accepted as an effective method to prevent infections by mounting pathogen-specific immune responses prior to the infection. Usually, immunization with vaccine antigens alone is not able to induce robust or long-lasting immune responses — resulting in failure of protective immunity against infections. Thus, adjuvants are required to enhance cellular or humoral immune responses upon immunization. Because vaccine adjuvants using Lipid A have proven to be safe and effective in inducing Th-1 type immune responses to heterologous proteins in animal and human vaccines, Avanti developed Phosphorylated HexaAcyl Disaccharide (PHAD™), the first fully synthetic monophosphoryl Lipid A available for use as an adjuvant in human vaccines.

Alkalmazás

MPLA PHAD™ has been used:
  • as a component of cobalt porphyrin-phospholipid (Co-PoP) liposomes for the immunization of mice with membrane proximal external region (MPER) of the gp41 envelope protein
  • as an adjuvant along with dimethyldioctadecylammonium bromide(DDA) for C. muridarum recombinant membrane protein based multi-subunit vaccine
  • as toll-like receptor-4 (TLR4) agonist adjuvant for respiratory syncytial virus (RSV) fusion (F) protein FI-RSV vaccine

Biokémiai/fiziológiai hatások

Monophosphoryl lipid A (MPLA) is a natural agonist for the toll-like receptor-4 (TLR4). It is useful as an adjuvant in immunization. MPLA is a safe prophylactic agent and has immunotherapeutic applications. MPLA used in vaccination improves B cell and T cell-mediated immunity.

Kiszerelés

2 mL Amber Glass Crimp Cap Vial (699800P-1mg)
2 mL Amber Glass Crimp Cap Vial (699800P-5mg)

Egyéb megjegyzések

For R&D use only. Not for drug, household, or other uses.

Jogi információk

Avanti Research is a trademark of Avanti Polar Lipids, LLC
PHAD is a trademark of Avanti Polar Lipids, LLC

Tárolási osztály kódja

11 - Combustible Solids

WGK

WGK 3

Lobbanási pont (F)

Not applicable

Lobbanási pont (C)

Not applicable

Analitikai tanúsítványok (COA)

Analitikai tanúsítványok (COA) keresése a termék sarzs-/tételszámának megadásával. A sarzs- és tételszámok a termék címkéjén találhatók, a „Lot” vagy „Batch” szavak után.

Már rendelkezik ezzel a termékkel?

Az Ön által nemrégiben megvásárolt termékekre vonatkozó dokumentumokat a Dokumentumtárban találja.

Dokumentumtár megtekintése

Construction of an Escherichia coli mutant producing monophosphoryl lipid A
Chen J, et al.
Biotechnology Letters, 33(5), 1013-1019 (2011)
Rhea N Coler et al.
PloS one, 5(10), e13677-e13677 (2010-11-10)
Safe, effective adjuvants that enhance vaccine potency, including induction of neutralizing Abs against a broad range of variant strains, is an important strategy for the development of seasonal influenza vaccines which can provide optimal protection, even during seasons when available
A recombinant anchorless respiratory syncytial virus (RSV) fusion (F) protein/monophosphoryl lipid A (MPL) vaccine protects against RSV-induced replication and lung pathology
Blanco JCG, et al.
Vaccine, 32(13), 1495-1500 (2014)
Susana Lousada-Dietrich et al.
Vaccine, 29(17), 3284-3292 (2011-02-26)
GMZ2 adjuvanted by aluminum hydroxide is a candidate malaria vaccine that has successfully passed phase 1 clinical testing in adult German and Gabonese volunteers and Gabonese children under five. Here we report a preclinical study screening a series of adjuvant
Caroline Boudousquié et al.
Vaccines, 8(1) (2020-01-18)
With the emergence of immune checkpoint inhibitors and adoptive T-cell therapies, there is a considerable interest in using personalized autologous dendritic cell (DC) vaccines in combination with T cell-targeting immunotherapies to potentially maximize the therapeutic impact of DC vaccines. Here
View All Related Papers

Tudóscsoportunk valamennyi kutatási területen rendelkezik tapasztalattal, beleértve az élettudományt, az anyagtudományt, a kémiai szintézist, a kromatográfiát, az analitikát és még sok más területet.

Lépjen kapcsolatba a szaktanácsadással